XTX Topco Ltd Takes $100,000 Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)

XTX Topco Ltd purchased a new position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 48,239 shares of the company’s stock, valued at approximately $100,000.

Several other hedge funds have also recently bought and sold shares of PRLD. Dimensional Fund Advisors LP boosted its position in Prelude Therapeutics by 103.2% during the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Prelude Therapeutics by 32.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after buying an additional 15,682 shares in the last quarter. Walleye Capital LLC grew its stake in Prelude Therapeutics by 446.2% in the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after acquiring an additional 67,946 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock valued at $362,000 after acquiring an additional 157,218 shares in the last quarter. Finally, State Street Corp raised its position in Prelude Therapeutics by 35.1% during the third quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after acquiring an additional 74,300 shares during the last quarter. 79.72% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Prelude Therapeutics

In related news, CEO Krishna Vaddi acquired 100,000 shares of the stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $0.93 per share, with a total value of $93,000.00. Following the purchase, the chief executive officer now directly owns 1,167,275 shares of the company’s stock, valued at approximately $1,085,565.75. This represents a 9.37 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 62.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a research report on Friday, November 8th.

Prelude Therapeutics Price Performance

Shares of NASDAQ PRLD opened at $1.30 on Friday. The company has a 50-day simple moving average of $1.21 and a 200-day simple moving average of $3.17. The company has a market cap of $71.55 million, a PE ratio of -0.73 and a beta of 1.49. Prelude Therapeutics Incorporated has a 12 month low of $0.80 and a 12 month high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last released its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. The firm had revenue of $3.00 million during the quarter. On average, analysts anticipate that Prelude Therapeutics Incorporated will post -1.81 EPS for the current year.

Prelude Therapeutics Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.